Tweet
Lancet Infect Dis
. 2024 Jul 24:S1473-3099(24)00461-4.
doi: 10.1016/S1473-3099(24)00461-4. Online ahead of print. Recombination as an evolutionary driver of MERS-related coronavirus emergence
Jarel Elgin Tolentino 1 , Spyros Lytras 2 , Jumpei Ito 3 , Edward C Holmes 4 , Kei Sato 5
Affiliations
No abstract available
PubMed Disclaimer
Conflict of interest statement
KS received consulting fees from Moderna and Takeda; honoraria for lectures from Gilead Sciences, Moderna, and Shionogi & Co; and is supported by the Agency for Medical Research and Development (AMED) Adopting Sustainable Partnerships for Innovative Research Ecosystem (ASPIRE), AMED Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA, AMED SCARDA Program on R&D of new generation vaccine including new modality application, AMED Research Program on Emerging and Re-emerging Infectious Diseases, Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (KAKENHI), and Mitsubishi UFJ Financial Group Vaccine Development Research Support. SL received consulting fees from EcoHealth Alliance. JI received consulting fees and honoraria for lectures from Takeda; and is supported by grants from Japan Science and Technology Agency PRESTO, JSPS KAKENHI Grant-in-Aid for Early-Career Scientists, and Mitsubishi UFJ Financial Group Vaccine Development Research Support. ECH received consulting fees and honoraria for lectures from Moderna and Pfizer; and is supported by grants from the National Health and Medical Research Council (NHMRC) Investigator award and AIR@InnoHK from the Innovation and Technology Commission (Hong Kong, China). JET is supported by a grant from the Japanese Government MEXT Scholarship-Research Category and declares no competing interests.
. 2024 Jul 24:S1473-3099(24)00461-4.
doi: 10.1016/S1473-3099(24)00461-4. Online ahead of print. Recombination as an evolutionary driver of MERS-related coronavirus emergence
Jarel Elgin Tolentino 1 , Spyros Lytras 2 , Jumpei Ito 3 , Edward C Holmes 4 , Kei Sato 5
Affiliations
- PMID: 39067463
- DOI: 10.1016/S1473-3099(24)00461-4
No abstract available
PubMed Disclaimer
Conflict of interest statement
KS received consulting fees from Moderna and Takeda; honoraria for lectures from Gilead Sciences, Moderna, and Shionogi & Co; and is supported by the Agency for Medical Research and Development (AMED) Adopting Sustainable Partnerships for Innovative Research Ecosystem (ASPIRE), AMED Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA, AMED SCARDA Program on R&D of new generation vaccine including new modality application, AMED Research Program on Emerging and Re-emerging Infectious Diseases, Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (KAKENHI), and Mitsubishi UFJ Financial Group Vaccine Development Research Support. SL received consulting fees from EcoHealth Alliance. JI received consulting fees and honoraria for lectures from Takeda; and is supported by grants from Japan Science and Technology Agency PRESTO, JSPS KAKENHI Grant-in-Aid for Early-Career Scientists, and Mitsubishi UFJ Financial Group Vaccine Development Research Support. ECH received consulting fees and honoraria for lectures from Moderna and Pfizer; and is supported by grants from the National Health and Medical Research Council (NHMRC) Investigator award and AIR@InnoHK from the Innovation and Technology Commission (Hong Kong, China). JET is supported by a grant from the Japanese Government MEXT Scholarship-Research Category and declares no competing interests.